Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
According to the recently published report 'Bromodomain Containing Protein 3 - Drugs In Development, 2022'; Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets.
The report 'Bromodomain Containing Protein 3 - Drugs In Development, 2022' outlays comprehensive information on the Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology and Immunology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoma, Melanoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Dermatitis (Eczema), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Unspecified B-Cell Lymphomas.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Roivant Sciences Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook